Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data

Journal of Nutrition, Health and Aging

Volumn 13, Issue 4, 2009, Pages 353-355

  Van Der Flier, W M ^a   Scheltens, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; FLOXURIDINE PHOSPHATE; ISOPROSTANE DERIVATIVE; TAU PROTEIN;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; HIPPOCAMPUS; HUMAN; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TEMPORAL LOBE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ATROPHY; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RESEARCH DESIGN;

EID: 65249187185     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12603-009-0041-x     Document Type: Article

References (22)

1. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002; 1(1):13-21.
2. Wolf H, Grunwald M, Kruggel F, Riedel-Heller SG, Angerhofer S, Hojjatoleslami A et al. Hippocampal volume discriminates between normal cognition; questionable and mild dementia in the elderly. Neurobiol Aging 2001; 22(2):177-186.
3. Petersen RC, Jack CRJ, Xu YC, Waring SC, O'Brien PC, Smith GE et al. Memory and MRI-based hippocampal volumes in aging and AD. Neurology 2000; 54:581-587.
4. Sluimer JD, van der Flier WM, Karas GB, Fox NC, Scheltens P, Barkhof F et al. Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology 2008; 248(2):590-598.
5. Henneman W.J., Sluimer JD, Barnes J, van der Flier WM, Sluimer IC, Fox N et al. Hippocampal atrophy rates in Alzheimer's disease: added value over whole brain volume measures. Neurology. 2009;(In Press)
6. Sluimer JD, Vrenken H, Blankenstein MA, Fox NC, Scheltens P, Barkhof F et al. Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology 2008; 70(19 Pt 2): 1836-1841.
7. Blennow K, Hampel H. - CSF markers for incipient Alzheimer's disease. - Lancet Neurol 2003 Oct;2(10):605-13(- 1474-4422 (Print)).
8. Wiltfang J, Lewczuk P, Riederer P, Grunblatt E, Hock C, Scheltens P et al. - Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. - World J Biol Psychiatry 2005;6(2):69-84(- 1562-2975 (Print)).
9. Bouwman FH, Schoonenboom SNM, van Der Flier WM, Van Elk EJ, Kok A, Barkhof F et al. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging 2007; 28(7):1070-1074.
10. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. - Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. - Lancet Neurol 2006 Mar;5(3):228-34(- 1474-4422 (Print)).
11. Bouwman FH, van der Flier WM, Schoonenboom NS, Van Elk EJ, Kok A, Scheltens P et al. Usefulness of Longitudinal Measurements of Beta-Amyloid1-42 in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders. Clin Chem 2006; 52(8):1604-1606.
12. Verwey NA, Bouwman FH, van der Flier WM, Veerhuis R, Scheltens P, Blankenstein MA. Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. Clin Chem Lab Med 2008; 46(9):1300-1304.
13. Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett 2007; 419(1):18-22.
14. Bouwman FH, van der Flier WM, Schoonenboom NS, Van Elk EJ, Kok A, Rijmen F et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007; 69(10):1006-1011.
15. Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. Neurobiol Aging 2008.
16. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE et al. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 2008; 29(10):1466-1473.
17. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55(3):306-319.
18. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68(7):501-508.
19. Jack CR, Jr., Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131(Pt 3):665-680.
20. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355(25):2652-2663.
21. Shin J, Lee SY, Kim SH, Kim YB, Cho SJ. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage 2008; 43(2):236-244.
22. Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst A et al. Detection of Alzheimer pathology in vivo using both [11C]PIB and [18F]FDDNP positron emission tomography. J Nucl Med. 2009;(In Press)